Targets › MAP2K4
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. (UniProt, P45985)
Open in Phaseline: the race on MAP2K4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of Xiamen University | Duvalisib Dual phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase 4 (MEK) | PIK3CA, PIK3CB, MAP2K4 | Phase 2 | Peripheral T Cell Lymphoma | Dec 2026 |
Peripheral T Cell Lymphoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.